MemoHoney Official Website › Articles › One ingredient
One ingredientBeta-alanine and the ageing hippocampus
Beta-alanine is the most interesting name on the MemoHoney label. A randomised trial gave 2.4 grams a day to men and women aged 60 to 80 and reported improved diffusion imaging scores in the hippocampus and amygdala. It is the only trial behind any ingredient here that measured something in a brain, in the right age group. The dose is several times what a shared capsule holds.
What beta-alanine actually is
Beta-alanine is an amino acid, and almost everything interesting about it is downstream. On its own it does very little. What it does is combine with histidine to make carnosine, a two-amino-acid molecule found in muscle and in the brain, and beta-alanine is the half that runs out first. Supply more of it and carnosine levels rise.
Carnosine buffers acid inside muscle cells, which is why beta-alanine became a sports supplement. It also has antioxidant and metal-binding properties in laboratory work, and it is present in neural tissue, which is why a small group of researchers started asking what it does there.
MemoHoney is a dietary supplement and not a treatment for anything. Nothing here is medical advice. Memory that has changed in a way you or the people around you have noticed is worth an appointment rather than a purchase, and MedlinePlus sets out what is worth reporting.
The sports evidence, which is the large part
Most of what is known about beta-alanine comes from exercise research, and there is a lot of it. A 2017 systematic review and meta-analysis pooled dozens of trials and found an effect on exercise capacity, concentrated in efforts lasting between about thirty seconds and ten minutes, which is the window where acid buildup limits performance.
A separate evidence review written for military use went through the benefit and safety case for personnel, and a systematic risk assessment and meta-analysis looked at harms across the literature. That is an unusually complete picture for a supplement ingredient.
The doses across that literature run 3.2 to 6.4 grams a day, usually split through the day to reduce tingling, and usually for four weeks or more before muscle carnosine rises enough to matter. Nothing about beta-alanine is fast.
The one trial that imaged a brain
In 2024, a randomised trial gave beta-alanine to men and women aged 60 to 80 and measured fractional anisotropy in the hippocampus and the amygdala using diffusion MRI. Fractional anisotropy is a measure of how directionally organised water movement is in tissue, and in white matter it is used as a proxy for structural integrity. The scores improved in the beta-alanine group.
The dose was 2.4 grams a day. The population was exactly the population a memory supplement is aimed at. That combination makes it the single most relevant piece of research behind any ingredient on this label, and it is worth describing precisely rather than gesturing at.
What the trial does show
- A randomised comparison rather than an observational association.
- An objective imaging measure rather than a questionnaire.
- The right age group: 60 to 80, not undergraduates.
- A specific, biologically plausible target in the hippocampus, which is where memory consolidation happens.
What it does not show
- That anybody remembered anything better. Imaging is a structural measure, not a cognitive outcome.
- That the effect persists, or that it grows, or that it matters clinically.
- That a smaller dose does anything. The trial used 2.4 grams a day.
- That it generalises. One trial is one trial, and replication is how this field decides anything.
2.4 grams a day is roughly three to five times what an entire once-daily capsule could hold, before it is shared with five other ingredients. This label prints no amount, so how far short it falls cannot be established from the pack. That is the honest position and it is not improved by restating the trial more enthusiastically.
See what every MemoHoney ingredient was tested at
Beta-alanine at 2.4 grams a day in the imaging trial, citrulline at 8.8, arginine AKG at 12. Every figure is printed beside its ingredient.
Two bottles $158 · six bottles $294 · 60-day money-back guarantee
Order MemoHoney From This CounterLot MEM-26/MA-5403 · one each morning, 30 to a bottle · ships from the United States
The carnosine trial, which points the same way
A second piece of research is worth knowing about because it approaches the same target from the other end. Rather than supplying beta-alanine and letting the body make carnosine, the NEAT trial supplied carnosine directly, at 2 grams a day for up to twelve weeks, and reported improved cognitive outcomes in younger participants.
That is a cognitive outcome rather than an imaging one, which makes it more directly interesting. It is also in a younger group, at a gram dose, of a different molecule. Taken together with the imaging trial, the carnosine story is the most promising thread in this whole ingredient list, and it is a thread rather than a conclusion.
The tingling, and why it is not a warning sign
Anybody who takes beta-alanine at a sports dose meets paraesthesia: a hot, prickling, pins-and-needles feeling across the face, neck and hands, starting fifteen or twenty minutes after a dose and passing within the hour. It is the most reliably reproduced effect of the ingredient.
The risk assessment put its odds ratio against placebo at 8.9, which sounds alarming and is not. A high odds ratio there reflects how specific the sensation is: almost nobody on placebo reports it, so any real incidence produces a large ratio. It is harmless, it fades with continued use, and it is dose-related.
At a shared capsule dose it is unlikely to happen at all. If it does, it is not an allergic reaction and it is not a reason to stop, though it is a reasonable thing to mention if you are checking a new supplement with somebody.
Why the hippocampus is the structure that got measured
The choice of structure in that trial is not arbitrary, and it is worth a paragraph because it explains why the result attracted attention at all.
The hippocampus is the part of the brain most directly involved in turning an experience into a memory that can be retrieved later. It is also one of the structures that changes earliest and most visibly with age and with Alzheimer's disease, which makes it the obvious target for anybody measuring whether an intervention has done something structural.
The amygdala, the other structure in the trial, sits beside it and is heavily involved in the emotional weighting that decides which experiences get consolidated strongly. Both are rich in carnosine relative to a lot of the rest of the brain, which is the reason a carnosine precursor was pointed at them rather than somewhere else.
| What was measured | What it is | What it is not |
|---|---|---|
| Fractional anisotropy | A diffusion MRI measure of how directionally constrained water movement is in tissue, used as a proxy for structural organisation | A test of memory, or a symptom anybody would notice |
| The hippocampus | The structure that consolidates experience into retrievable memory | The whole of memory, which is distributed across many regions |
| The amygdala | Emotional weighting, which influences what gets consolidated | A measure of mood or of anything the participants reported |
| A randomised design | The strongest available control for expectation | A guarantee of replication, which is a separate question |
An imaging endpoint is a real measurement and a long way from a clinical one. Both halves of that sentence matter.
That is why this article calls the trial interesting rather than conclusive. A structural change in the right tissue, in the right age group, under randomisation, is a good reason to run a larger trial with a cognitive endpoint. It is not a reason to describe a capsule as proven, and nothing on this website does.
Where that leaves beta-alanine on this label
It is, on the evidence, the most interesting name in the list. It has the only randomised trial in the right age group with a brain measurement attached, a companion trial on the same molecule from a different direction, a well-characterised safety profile, and a plausible mechanism in tissue that matters.
It is also present in an unknown amount, alongside five other ingredients, in a capsule that cannot hold a gram of anything. Both of those sentences are true at once, and a reader deciding whether to buy needs both.
The awkward consequence is that the best argument for this label is also the best argument against buying it in this form. If the imaging trial is what convinces you, the thing it convinces you of is 2.4 grams a day of a single ingredient, and that is a powder rather than a capsule. If the convenience of one capsule a morning is what convinces you, the beta-alanine evidence is not really what you are buying. Being clear about which of those two you are doing is most of the decision.
- If beta-alanine is the reason you are interested, the trial dose is 2.4 grams a day and it is sold as a standalone powder for a fraction of what any capsule costs.
- If you want the convenience of a once-daily capsule, accept that the amount is unknown and judge the product on its other merits.
- Either way, read the ingredients page and the mechanism page before deciding, because the rest of the label rests on a different argument entirely.
- Printed in 2024, “β-Alanine supplementation improves fractional anisotropy scores in the hippocampus and amygdala in 60-80-year-old men and women” (Ostfeld I, Zamir A, Ben-Zeev T, et al; Exp Gerontol, 194:112513) — PubMed record 38971131.
- Printed in 2017, “β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis” (Saunders B, Elliott-Sale K, Artioli GG, et al; Br J Sports Med, 51(8):658-669) — PubMed record 27797728.
- Printed in 2019, “A Systematic Risk Assessment and Meta-Analysis on the Use of Oral β-Alanine Supplementation” (Dolan E, Swinton PA, Painelli VS, et al; Adv Nutr, 10(3):452-463) — PubMed record 30980076.
- Printed in 2014, “Evidence-based evaluation of potential benefits and safety of beta-alanine supplementation for military personnel” (Ko R, Low Dog T, Gorecki DK, et al; Nutr Rev, 72(3):217-25) — PubMed record 24697258.
- Printed in 2025, “Carnosine supplementation improves cognitive outcomes in younger participants of the NEAT trial” (O'Toole TE, Amraotkar AR, Gao H, et al; Neurotherapeutics, 22(2):e00541) — PubMed record 39919936.
- MedlinePlus, US National Library of Medicine: “Memory” — medlineplus.gov.
